Anticipated $-0.10 EPS for Protalix BioTherapeutics, Inc. (PLX) as of May, 9

April 17, 2018 - By Sonya McDaniel

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Corporate Logo

On May, 9 is awaited Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX)’s earnings report, Faxor reports. The EPS diference is $0.03 or 42.86 % down from last years number. Previous year: $-0.07; Analysts forcast: $-0.10. Wall Street now sees 0.00 % EPS growth despite Protalix BioTherapeutics, Inc. last quarter’s EPS of $-0.10. Its shares touched $0.452 on during the last trading session after 3.83% change.Protalix BioTherapeutics, Inc. has volume of 279,296 shares. Since April 17, 2017 PLX has declined 55.56% and is downtrending. The stock underperformed the S&P 500 by 67.11%.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally.The company has $65.80 million market cap. The firm offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.Last it reported negative earnings. The Company’s product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis.

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.